Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States.
Share Price & News
How has Allied's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALID is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: ALID's weekly volatility has decreased from 29% to 20% over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: ALID exceeded the US Pharmaceuticals industry which returned 11% over the past year.
Return vs Market: ALID underperformed the US Market which returned 33.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Allied's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Allied Fundamentals Summary
|ALID fundamental statistics|
Is ALID overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALID income statement (TTM)|
|Cost of Revenue||US$227.26k|
Last Reported Earnings
May 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.13|
|Net Profit Margin||-200,530.23%|
How did ALID perform over the long term?See historical performance and comparison
Is Allied undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALID's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALID's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALID is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ALID is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALID's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALID is overvalued based on its PB Ratio (53.7x) compared to the US Pharmaceuticals industry average (3.2x).
How is Allied forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Allied has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Allied performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ALID is currently unprofitable.
Growing Profit Margin: ALID is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ALID's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ALID's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALID is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: ALID has a negative Return on Equity (-374.76%), as it is currently unprofitable.
How is Allied's financial position?
Financial Position Analysis
Short Term Liabilities: ALID's short term assets ($1.6M) do not cover its short term liabilities ($4.8M).
Long Term Liabilities: ALID's short term assets ($1.6M) exceed its long term liabilities ($67.1K).
Debt to Equity History and Analysis
Debt Level: ALID's debt to equity ratio (116.3%) is considered high.
Reducing Debt: Insufficient data to determine if ALID's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALID has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ALID is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.
What is Allied current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALID's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALID's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALID's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALID's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Calum Hughes serves as Founder, Chairman, Chief Executive Officer and Director of Allied Corp. He has been responsible for leading activities relating to large scale Quality Assurance and Evaluation of...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Allied Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Allied Corp.
- Ticker: ALID
- Exchange: OTCPK
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$150.981m
- Shares outstanding: 80.31m
- Website: https://allied.health
- Allied Corp.
- 1405 St. Paul Street
- Suite 201
- British Columbia
- V1Y 2E4
Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp derived natural health product...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/19 22:16|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.